Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aji Istadi

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Nature Biotechnology|December 20, 2023
Cancer variant modeling in vivoAji Istadi, Sean Porazinski, Marina Pajic
Advanced Genetics (Hoboken, N.J.)|March 13, 2023
A CRISPR Path to Finding Vulnerabilities and Solving Drug Resistance: Targeting the Diverse Cancer Landscape and Its EcosystemBenjamin McLean, Aji Istadi, Teleri Clack, et al.
Frontiers in Oncology|December 16, 2021
Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of <i>EGFR</i> Amplification: Implications for Novel Personalized TherapyLaveniya Satgunaseelan, Sean Porazinski, Dario Strbenac, et al.
Molecular Cancer Therapeutics|July 7, 2025
Integration of whole genome sequencing analysis with unique patient-derived models reveals clinically relevant drug targets in TFCP2 fusion-defined rhabdomyosarcomaPatrick Bergsma, Sean Porazinski, Aji Istadi, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Nature Biotechnology|December 20, 2023
Cancer variant modeling in vivoAji Istadi, Sean Porazinski, Marina Pajic
Advanced Genetics (Hoboken, N.J.)|March 13, 2023
A CRISPR Path to Finding Vulnerabilities and Solving Drug Resistance: Targeting the Diverse Cancer Landscape and Its EcosystemBenjamin McLean, Aji Istadi, Teleri Clack, et al.
Frontiers in Oncology|December 16, 2021
Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of <i>EGFR</i> Amplification: Implications for Novel Personalized TherapyLaveniya Satgunaseelan, Sean Porazinski, Dario Strbenac, et al.
Molecular Cancer Therapeutics|July 7, 2025
Integration of whole genome sequencing analysis with unique patient-derived models reveals clinically relevant drug targets in TFCP2 fusion-defined rhabdomyosarcomaPatrick Bergsma, Sean Porazinski, Aji Istadi, et al.
Pageof 1